POMDOCTOR Ltd Annual Report - How They Did This Year

I’ve put together this guide to help you understand how POMDOCTOR Ltd performed this year. My goal is to break down their complex filings into plain English so you can decide if this company fits your portfolio.

1. What does this company do?

POMDOCTOR acts as an online bridge between patients and healthcare in China. They run a digital platform where patients register, consult with doctors, and buy medicine. They don’t own clinics; instead, they manage a network of contracted doctors who provide advice and prescriptions. They make money by charging service fees for consultations and selling medicine directly to users.

2. Financial Performance: The "Big Picture"

The company is growing, but it is not yet profitable. In fact, their losses grew significantly this year. They spent heavily on marketing, building their platform, and managing their network of doctors.

• Revenue (Total Sales): They brought in 400 million RMB in 2025, up from 343 million in 2024 and 305 million in 2023. It is encouraging to see more people using the platform.
• Profit/Loss: Despite higher sales, the company lost 131 million RMB in 2025. This is a sharp jump from the 37 million RMB loss reported in both 2024 and 2023.

The takeaway: While the business is growing, the costs to run it—especially maintaining the technology and finding new users—are outpacing their income. They are currently in a "growth at all costs" phase.

3. Financial Health: The "Safety Net"

At the end of 2025, the company had about 9.6 million RMB in cash. Given the 131 million RMB loss this year, their cash position is very tight. They rely on managing their daily bills and potentially raising more money to keep operating. They are a "holding company" based in the Cayman Islands. They don't own the Chinese operations directly; they use a complex contract structure to control the local entities that hold the necessary operating licenses.

4. Major Risks: The "Fine Print"

This is the most important part for you to understand:

• The "VIE" Structure: Because China restricts foreign ownership of medical companies, POMDOCTOR uses a contract-based structure. You aren't buying a piece of the actual Chinese company; you are buying a contract that claims to give you the economic benefits of that company. If the Chinese government decides this structure is invalid, your investment could become worthless.
• Cash Flow Restrictions: Moving money out of China is difficult. The government has strict rules on currency and borders. The company’s ability to pay you dividends depends on their Chinese subsidiaries following local rules. There is no guarantee they will ever be able to pay dividends to international shareholders.

5. Future Outlook

The company is betting on the growth of online healthcare in China. However, they are at the mercy of government regulators. New rules regarding data privacy, medical standards, or internet content could appear at any time. Such shifts could force them to change their business model or increase costs, which would impact their ability to reach profitability.

Final Thought for Your Portfolio: When considering this investment, weigh the company's consistent revenue growth against its rising losses and the high-risk legal structure. Because the company is currently burning cash faster than it earns it, you should consider whether you are comfortable with the potential need for future capital raises and the regulatory uncertainty inherent in their business model.